GlassScriptPhysician profile
Daniel G Hartman
NPI 1497827125
$4,907.92
in general payments reported to CMS, 2019-2025
26 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $241 · 2021: $763 · 2022: $651 · 2023: $1,266 · 2024: $1,327 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,794 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,793.88 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $876.33 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $569.75 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $327.40 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $302.66 | 2022-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $297.78 | 2019-2024 | Rexulti |
| Lundbeck LLC | $271.41 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $239.51 | 2020-2024 | Trintellix |
| Corium, LLC | $239.22 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $229.49 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $224.90 | 2019-2023 | Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $206.37 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $204.33 | 2019-2022 | |
| Axsome Therapeutics, INC. | $176.57 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $145.27 | 2019-2024 | |
| Allergan, INC. | $95.73 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $95.52 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $92.51 | 2023-2024 | Quviviq |
| Almatica Pharma LLC | $83.91 | 2023-2024 | Loreev Xr |
| Vertical Pharmaceuticals, LLC | $50.60 | 2019-2024 | Relexxii |
| Neuronetics, INC. | $49.59 | 2019 | |
| Owp Pharmaceuticals, INC. | $31.00 | 2019 | |
| Shire North American Group INC | $26.85 | 2019 | |
| Collegium Pharmaceutical, INC. | $22.09 | 2025 | Jornay Pm |
| Tris Pharma INC | $19.60 | 2023 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $17.80 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hartman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.